MYRALACT

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H35NO.C3H6O3
Molecular Weight	347.5331
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.CCCCCCCCCCCCCCNCCO

InChI

InChIKey=HLFJBIVEMZFFOG-UHFFFAOYSA-N

InChI=1S/C16H35NO.C3H6O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-15-16-18;1-2(4)3(5)6/h17-18H,2-16H2,1H3;2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4946150 | http://www.un.org/Depts/oip/cpmd/010302health.pdf

Myralact is an antiseptic included in multi-ingredient preparations, e.g. vaginal tablets Ginetris, intended for the topical treatment of vaginal infections.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Vaginal trichomoniasis 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4946150	Curative		Not Provided 504	Ginetris Approved Use Unknown

PubMed

Title	Date	PubMed

Sample Use Guides

In Vivo Use Guide

re-treated with a course of Ginetris vaginal tablets (chloramphenicol 250 mg.; myralact 10 mg.; cloponone 2.5 mg.); one tablet was inserted twice daily for 5 days and this was followed by a single dose of 2 g. metronidazole.

Route of Administration: Vaginal

In Vitro Use Guide

Unknown

Name

Type

Language

MYRALACT

Official Name

English

2-(TETRADECYLAMINO)ETHANOL LACTATE

Systematic Name

English

Myralact [WHO-DD]

Common Name

English

myralact [INN]

Common Name

English

MYRALACT [MART.]

Common Name

English

Code System Code Type Description

INN

1767